A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) for People With Recurrent Glioblastoma With Elevated Mutational Burden
Conditions: Glioblastoma, IDH-Mutant; Recurrent Glioblastoma Interventions: Biological: Ipilimumab; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials